/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

XORTX Therapeutics Inc share price today is $0.44, up -4.23%. The stock opened at $0.4699 against the previous close of $0.4699, with an intraday high of $0.4699 and low of $0.4451.

style

pb-0

XORTX Therapeutics Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.44 -0.0423(-4.23%) XRTX at 13 Mar 2026 03:58 PM Biotechnology

Lowest Today 0.4451

Highest Today 0.4699

Today’s Open 0.4699

Prev. Close 0.4699

52 Week High 1.41

52 Week Low 0.37

Day’s Range: Low 0.4451 High 0.4699

52-Week Range: Low 0.37 High 1.41

XORTX Therapeutics Inc Institutional Holdings

XORTX Therapeutics Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

XORTX Therapeutics Inc Fundamentals

Market Cap 3.27 M

PB Ratio 1.5695

PE Ratio 0.0

Enterprise Value 2.25 M

Total Assets 3.68 M

Volume 15733

XORTX Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-6706471 -6.7M, FY22:-6988881 -7.0M, FY21:-1295887 -1.3M, FY20:-1284602 -1.3M, FY19:-629576 -0.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-29059 -0.0M, Q2/2025:-28085 -0.0M, Q1/2025:-25906 -0.0M, Q3/2024:null 0.0M, Q2/2024:-33042 -0.0M

Quarterly Net worth Q3/2025:-642268 -0.6M, Q2/2025:-729525 -0.7M, Q1/2025:-696561 -0.7M, Q3/2024:-587011 -0.6M, Q2/2024:170066 0.2M

About XORTX Therapeutics Inc & investment objective

Company Information XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO Dr. Allen Warren Davidoff Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*